Vinorelbin 30 mg (Capsule)
Unit Price: ৳ 5,750.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Vinorelbine tartrate |
| Company | Lotus pharmaceutical co ltd taiwan |
Indications
- First-line treatment of locally advanced or metastatic non-small cell lung cancer in combination with cisplatin
- Treatment of metastatic non-small cell lung cancer as a single agent
Pharmacology
- Binds to tubulin
- Inhibits microtubule formation
- Disrupts formation of the mitotic spindle
- Arrests the cell at metaphase
Dosage & Administration
- Intravenous administration for cervical cancer, breast cancer, and ovarian cancer
- Intravenous administration for non-small cell lung cancer as a single agent or in combination with cisplatin
- Oral administration for non-small cell lung cancer
- Dosage adjustments for hepatic impairment
Interaction
- Increased risk of granulocytopenia with cisplatin
- Increased risk of neurotoxicity with paclitaxel, itraconazole, or ketoconazole
- Increased radiosensitizing effects with prior or concomitant radiation therapy
- Increased pulmonary toxicity with mitomycin
- Increased myelotoxicity with zidovudine
- Earlier onset and/or increased severity of side effects with CYP3A inhibitors
- Possible increase in vincristine levels with aprepitant
- Possible infection with live vaccines
Contraindications
- Hypersensitivity to vinorelbine or other vinca alkaloids
- Severe current or recent infection
- Neutropenia
- Thrombocytopenia
- Severe hepatic impairment
- Intrathecal administration
- Concomitant use with radiotherapy if liver is in treatment field
- Pregnancy
- Lactation
Side Effects
- Neurotoxicity
- Peripheral paraesthesia
- Loss of deep tendon reflexes
- Abdominal pain
- Severe constipation
- Diarrhea
- Alopecia
- Severe local irritation
- Granulocytopenia
- Leukopenia
- Anemia
- Intestinal obstruction
- Paralytic ileus
- Nausea
- Vomiting
- Increased liver function test
- Chest pain
- Fatigue
- Local pain and thrombophlebitis with repeated injection
Pregnancy & Lactation
- Pregnancy Category D
- Positive evidence of human fetal risk
- Benefits from use in pregnant women may be acceptable despite the risk
Precautions & Warnings
- Hepatic impairment
- Compromised bone marrow reserve
- Prior or pre-existing neuropathy
- Monitoring of CBC with differentials
- Administration guidelines for intravenous and oral administration
- Recommendations for contraception during and after treatment
Use in Special Populations
- Dose adjustments for hepatic impairment
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Intravenous storage at 2-8°C, protected from light
- Oral storage at 2-8°C